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Summary 31 
The autoimmune regulator (AIRE) gene is crucial for establishing central immunological 32 
tolerance and the prevention of autoimmunity. Mutations in AIRE cause a rare autosomal 33 
recessive disease, autoimmune polyendocrine syndrome type 1 (APS-1), distinguished by 34 
multi-organ autoimmunity. We here report multiple cases and families with mono-allelic 35 
mutations in the first plant homeodomain (PHD1) zinc finger of AIRE, which follow 36 
dominant inheritance, typically characterized by later onset, milder phenotypes, and 37 
reduced penetrance compared to classical APS-1. These missense PHD1-mutations 38 
suppress gene expression driven by wild type AIRE in a dominant negative manner, unlike 39 
CARD or truncated AIRE mutants, which lack such dominant capacity.  Strikingly, exome 40 
array analysis revealed that the PHD1 dominant mutants are found with relatively high 41 
frequency (> 0.0008) in populations.  Our results provide novel insight into the molecular 42 
action of AIRE and demonstrate that disease-causing mutations in the AIRE locus are more 43 
common and variable than previously appreciated. 44 
  45 
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INTRODUCTION 46 
The autoimmune regulator (AIRE) is a key player in shaping central immunological tolerance 47 
to self. AIRE is mainly expressed in medullary thymic epithelial cells (mTECs), but to some 48 
extent also in rare hematopoietic populations of lymph nodes (Gardner et al., 2008). In 49 
mTECs, AIRE induces expression of thousands of tissue-restricted proteins, which are 50 
presented on major histocompatibility complex class I (MHC-I) and MHC-II molecules to 51 
developing T cells, ƉĞƌĐŽůĂƚŝŶŐƚŚƌŽƵŐŚƚŚĞƚŚǇŵŝĐŵĞĚƵůůĂ ?dŚŝƐ “ƉƌŽũĞĐƚŝŽŶŽĨƐĞůĨ ?by 52 
mTECs is essential for the elimination of auto-reactive T cells, either via clonal deletion 53 
(Taniguchi and Anderson, 2011) or via their conversion into Foxp3+ regulatory T cells (Cowan 54 
et al., 2013); a critical step for the induction of functional immunological tolerance to self 55 
and prevention of autoimmunity (Taniguchi and Anderson, 2011). 56 
In humans, mutations in the AIRE gene cause autoimmune polyendocrine syndrome 57 
type 1 (APS-1), also called autoimmune polyendocrinopathy Wcandidiasis Wectodermal 58 
dystrophy (APECED), a rare autosomal recessive disease characterized by autoimmune 59 
attack against peripheral (mainly endocrine) tissues, as well as by generation of various 60 
autoantibodies, including interferon-specific autoantibodies (Meager et al., 2006). The 61 
majority of APS-1 patients develop at least two (diagnostic dyad) of the three main 62 
components, including adrenocortical insufficiency, hypoparathyroidism and chronic 63 
mucocutaneous candidiasis (Ahonen et al., 1990; Husebye and Anderson, 2010). In addition, 64 
premature ovarian insufficiency, pernicious anemia, vitiligo, alopecia, enamel hypoplasia, 65 
and keratitis are common components. The disease typically manifests in childhood, but 66 
milder forms with late debut are seen, which are not always recognized as APS-1 at first.  67 
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About 100 APS-1-causing mutations have been found throughout the AIRE gene 68 
(http://www.hgmd.cf.ac.uk) (Ferguson et al., 2008). All are assumed to be inherited in an 69 
autosomal recessive manner, except for one mutation in the SAND-domain, p.G228W, which 70 
follows a dominant inheritance pattern (Cetani et al., 2001). Since AIRE is known to operate 71 
as a homo-oligomer (Kumar et al., 2001; Pitkanen et al., 2000), it is rather surprising that 72 
only one mono-allelic mutation in the AIRE locus has been linked to APS-1 and/or other 73 
forms of organ-specific autoimmune disorders so far.  74 
Based on analysis of human patients followed by biochemical and population 75 
analyses, we here report a group of novel mono-allelic AIRE mutations. These mutations 76 
cluster within the first plant homeodomain (PHD1) zinc finger domain, associate with organ-77 
specific autoimmune diseases with varying penetrance and severity, sometimes, but often 78 
not matching the diagnostic criteria of APS-1. Furthermore, we delineate the molecular 79 
mode of action by which these unique mutations interfere with the function of wild type 80 
(WT) AIRE protein. Our results provide novel insights into the molecular action of the AIRE 81 
protein and indicate that disease-causing mutations in the AIRE locus are much more 82 
common than previously thought and can cause more variable autoimmune phenotypes. 83 
 84 
RESULTS 85 
Novel p.C311Y AIRE mutant exerts a dominant negative effect  86 
The study was initiated by the discovery of  a heterozygous c.932G>A (p.C311Y) mutation in 87 
AIRE in a North-African patient (I:2, Figure 1A, Table 1 and Table S1) diagnosed with adult-88 
onset of chronic mucocutaneous candidiasis, adrenal insufficiency, enamel dysplasia, 89 
pernicious anemia, partial diabetes insipidus, and interferon omega autoantibodies (Figure 90 
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1A). Importantly, no other mutations or copy number variations were detected. His family 91 
history revealed a daughter (II:1, with partner 1) who had hypoparathyroidism, enamel 92 
dysplasia, primary ovarian insufficiency, autoimmune gastritis, pernicious anemia, and the 93 
same mono-allelic p.C311Y mutation indicating dominant inheritance. With his second 94 
partner (I:3), he had four children of whom three carried the mono-allelic p.C311Y mutation 95 
and developed  various forms autoimmunity; one daughter (II:2) had alopecia areata and nail 96 
dystrophy on one of ten finger nails, another daughter (II:4) had hypoparathyroidism, and 97 
primary ovarian insufficiency, while a son (II:3) was diagnosed with autoantibodies against 98 
tyrosine hydroxylase (often associated with APS-1) (Hedstrand et al., 2000), but otherwise 99 
had no autoimmune manifestations (Figure 1A, Table 1 and Table S1). To exclude autosomal 100 
recessive inheritance at the AIRE locus, we performed microsatellite markers analysis, which 101 
validated that the affected children had indeed inherited different maternal AIRE alleles 102 
(Figure S1). 103 
We next analyzed if p.C311Y can repress the transcription-transactivation potential 104 
of WT AIRE in a dominant negative manner. To this end we utilized the human thymic 105 
epithelial 4D6 cell line, which was transfected with either WT-AIRE and/or mutated AIRE 106 
expression vectors. We then measured the mRNA expression of a panel of AIRE-dependent 107 
(KRT14, S100A8 and IGFL1) and  Windependent genes (CCNH and PRMT3) (Giraud et al., 108 
2012). As expected, the WT-AIRE induced strong expression of all analyzed AIRE-dependent 109 
genes, whereas p.C311Y, p.G228W, p.L28P and the deleterious major Finnish mutation 110 
p.R257* did not (Figure 1B, Figure S2). No differences among the WT-AIRE or AIRE mutants 111 
were seen for AIRE-independent genes (Figure 1B, Figure S2). Strikingly, when 4D6 cells 112 
were co-transfected with different ratios of WT-AIRE and the above mutants, p.C311Y 113 
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completely abolished the ability of WT-AIRE to induce expression of AIRE-dependent genes 114 
(Figure 1B, Figure S2), as did the previously reported SAND domain mutant p.G228W 115 
(dominant negative control) (Su et al., 2008). Conversely, neither p.R257* nor the p.L28P 116 
CARD mutation showed this inhibiting effect (recessive controls). Taken together, these data 117 
validate that the p.C311Y mutant exerts a dominant negative effect on WT AIRE function, 118 
both in vitro and in human patients. 119 
 120 
Identification of dominant-negative variants of AIRE  121 
As the phenotype in family A segregated with a heterozygous mutation in AIRE with an 122 
inhibitory effect on transcription of AIRE-dependent genes, we asked if there might be more 123 
dominant AIRE mutations. To test this hypothesis we generated a panel of expression 124 
vectors with reported disease-causing mutations including several located in the PHD1, 125 
CARD, and SAND domains (Figure 2A). First we tested the dominant negative effect of AIRE-126 
mutants in co-transfection experiments with WT-AIRE in 4D6 cells. Similarly to the p.C311Y 127 
mutation, virtually all missense mutations in the PHD1 finger, including p.E298K, p.V301M, 128 
p.C302Y, p.R303P, p.G305S, p.D312N, and p.P326L revealed a dominant negative effect on 129 
AIRE-dependent genes (Figure 2B, Figure S3, Table S3). Interestingly, the dominant negative 130 
effect of p.V301M varied with the downstream gene tested (Figure 2B, Figure S3 in the 131 
Supplement), which was surprising but reproducible in several independent experiments.  In 132 
contrast, ŵŽƐƚŽĨ/Z ?ƐCARD mutants, as well as the truncated PHD1-mutant p.C311* 133 
revealed a clear recessive pattern, while the common p.C322del13, p.R328Q and p.C446G 134 
displayed only a partial dominant effect (Figure 2B, Figure S3, Table S3). Conversely, p.R471C 135 
(PHD2 domain) had no effect on AIRE-dependent gene transcription (Figure 2B, Figure S3, 136 
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Table S3). As expected, AIRE-independent transcriptional activity was not affected in any of 137 
these analyses (Figure 2B, Figure S3). This series of experiments demonstrated that the 138 
heterozygous mutations in AIRE can be segregated into three groups according to their 139 
potential to impact on the transcription-transactivation potential of WT AIRE in; (i) dominant 140 
negative, (ii) recessive, and (iii) partial dominant negative manners. Moreover, our data 141 
revealed that most of the mutations operating in a dominant negative manner are clustered 142 
within the PHD1 finger, while most recessive mutations were clustered within the CARD 143 
domain.  144 
 145 
Dominant negative mutants physically co-localize with WT AIRE 146 
To better understand the unique properties of the dominant mutants, we next analyzed 147 
their nuclear localization patterns. 4D6 cells were co-transfected with red fluorescent 148 
protein (RFP)-tagged WT AIRE plasmids together with expression vectors encoding individual 149 
AIRE mutants tagged with enhanced green fluorescent protein (EGFP). Importantly, all 150 
dominant mutants, including the PHD1 missense mutations, localized in nuclear speckles 151 
typical for WT-AIRE and co-localized with WT-AIRE protein (yellow overlay) (Figure 3A and 152 
Figure S4, Table S2 and S3 ). In contrast, recessive CARD mutants (p.L28P, p.LL28_29PP; 153 
p.Y90C; p.L97P) which are thought to disrupt AIRE homo-oligomerization (Kumar et al., 2001; 154 
Pitkanen et al., 2001), failed to provide the same speckles and stained diffusely throughout 155 
the nucleus when transfected alone. In co-transfections, however, all CARD mutants partly 156 
co-localized with WT-AIRE, indicating that when co-expressed some functional oligomers are 157 
able to form.  158 
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Since virtually all analyzed PHD1 mutants demonstrated a dominant negative effect, 159 
we sought to gain more insights about the impact of these mutants on molecular structure 160 
of this domain. Specifically, in silico analysis predicted that the p.C311 residue is crucial for 161 
chelating Zn
2+
, and thereby is critical for correct folding of the PHD1 finger. Indeed, a 162 
substitution of the cysteine with tyrosine is predicted to disrupt PHD1 folding (Chakravarty 163 
et al., 2009) (Figure 3B). Additional structural analyses revealed that many of the reported 164 
missense mutations changed amino acids that are conserved among different species 165 
(Bjorses et al., 2000; Org et al., 2008; Spiliotopoulos et al., 2012) (Figure S5), and can 166 
similarly affect the Zn
2+
-binding or folding of the domain. 167 
Taken together, these data suggest that most of the PHD1 mutants can, unlike their 168 
CARD mutant counterparts, physically associate with WT AIRE in nuclear speckles and form a 169 
homo-oligomer, which is however not functional due to dysfunctional PHD1 fingers.  170 
 171 
Proof of concept ʹ additional PHD1 dominant-negative AIRE mutations segregate with 172 
organ-specific autoimmunity  173 
Our in-vitro analyses predicted that in addition to the p.C311Y mutation, more dominant 174 
mutations are clustered within the PHD1 finger and may therefore similarly cause organ-175 
specific autoimmunity in human patients. To validate this hypothesis, we performed a 176 
thorough analysis of patient cohorts available to us. First, we reinvestigated a previously 177 
described case, in which p.C311Y had been reported as a compound heterozygous mutation 178 
with p.R257* in two Finnish siblings with childhood-onset of APS-1 (Bjorses et al., 2000) 179 
(Table 1, (Family B, II:3 and II:4), Figure 4A and Table S1). Re-sequencing AIRE in this family 180 
confirmed the earlier report, but also revealed that one of the affected siblings ? son (III:1) 181 
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had inherited p.C311Y, but not p.R257*. He manifested with vitiligo and severe pernicious 182 
anemia due to autoimmune gastritis at young age. Moreover, the maternal grandmother 183 
(I:2), also a heterozygous p.C311Y carrier, was diagnosed with pernicious anemia and several 184 
autoantibodies characteristic of APS-1 (Table 1, Figure 4A and Table S1). In contrast, the 185 
third daughter (II:1), a heterozygous carrier of p.R257*, was without detectable 186 
autoantibodies.  187 
 Next, we reinvestigated a woman with APS-2 characterized by adrenal insufficiency, 188 
autoimmune thyroid disease, primary ovarian insufficiency and autoantibodies characteristic 189 
of APS-I with a mono-allelic c.901G>A (p.V301M) mutation (Table 1 (Family C), Figure 4A and 190 
Table S1) (Soderbergh et al., 2000). Her daughter also with a p.V301M mutation, had 191 
autoantibodies against IL-17F, which are often found in APS-1 patients. However, she did not 192 
present with any additional autoimmune manifestations at age 30 years. Finally, additional 193 
screening of a large cohort of 85 Russian APS-1 patients and some of their family members 194 
identified a young girl with a mono-allelic p.C302Y mutation, who developed 195 
hypoparathyroidism and autoantibodies against interferon omega, NALP-5 and 21-196 
hydroxylase (Table 1 (subject D). Like p.C311Y, p.C302Y revealed dominant negative effects 197 
on AIRE-mediated transcription (Figure 2B, Figure S3 and Table S3). A very similar case with 198 
a de novo mono-allelic p.C302Y mutation was reported by us earlier (Oftedal et al., 2008) 199 
(Table 1 (subject E)).  200 
In summary, our data illustrate that individuals with bi-allelic disease-causing AIRE 201 
mutations develop classic early onset APS-1 phenotypes, while those carrying one of three 202 
different mono-allelic mutations in the PHD1 finger (p.C311Y, p.V301M and p.C302Y) 203 
segregate with clear, but varying autoimmune phenotypes, ranging from late-onset classical 204 
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APS-1 (e.g. I:3, Figure 1A ), to APS-2 (Table 1, Figure 4B and Table S1), and isolated organ-205 
specific autoimmunity (e.g. vitiligo, PA, and APS-1-specific auto-antibodies). 206 
 207 
Increased frequency of dominant PHD1 mutations in various forms of organ-specific 208 
autoimmunity 209 
The above findings raised the question whether dominant PHD1 mutations could generally 210 
cause organ-specific autoimmunity. To answer this question, we sequenced the full exon 8 211 
(encoding the PHD1 finger) in several autoimmune patients and controls available to us from 212 
our national registry. We first analyzed the presence of PHD1 mutants in familial cases 213 
characterized by the presence of adrenal insufficiency, autoimmune thyroid disease and/or 214 
type 1 diabetes (i.e. APS-2 and /or APS-3). Indeed, among 41 such families, we identified one 215 
family with three family members bearing a mono-allelic c.977C>T (p.P326L) mutation (Table 216 
1 (Family F), Figure 4A and Table S1). The mother (II:3) was diagnosed with autoimmune 217 
thyroid disease, adrenal insufficiency, pernicious anemia and vitiligo. Her children both 218 
acquired vitiligo at 10 (III:1) and 7 (III:2) years of age, respectively.  219 
Furthermore, since pernicious anemia, vitamin B12 deficiency, and/or vitiligo seemed 220 
to be often associated with heterozygous PHD1 mutations in previous cases (Figure 4B), we 221 
next screened large cohorts of patients with these conditions. Among 177 probands and 26 222 
affected relatives with pernicious anemia, we identified several dominant negative PHD1 223 
mutants; First, a patient with a heterozygous c.913G>A (p.G305S) mutation who was 224 
intrinsic factor (IF) antibody positive and developed severe anemia and neuropathy at age 43 225 
(Table 1, (Family G), Figure 4A and Table S1). Her mother (II:2) and maternal grandmother 226 
(III:2) were reported to have pernicious anemia, the mother also suffered from 227 
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hypothyroidism and cirrhosis. p.G305S is close to the zinc binding site and predictably 228 
disrupts the zinc finger structure. Not surprisingly, the dominant negative effect on gene 229 
transcription was evident (Figure 2B, Figure S3 and Table S3). Another patient in this cohort 230 
developed intrinsic factor antibody positive pernicious anemia at age 81 years and was 231 
heterozygous for both c.946C>T (p.R316W) and the common c.967-979del13bp 232 
(p.C322del13) mutation on the same allele (Table 1 and Table S1 (subject H)). Both p.R316W 233 
and (p.C322del13) were predicted to have a partial dominant negative effect.  234 
Similarly, among 170 patients with isolated and familial (n=64) vitiligo, a female who 235 
developed acrofacial vitiligo at age 21 years, with gastric parietal cell autoantibodies, low 236 
normal serum vitamin B12 level , and a heterozygous mutation in c.983G>A (p.R328Q) (Table 237 
1 (subject I) and Table S1). Like p.P326L, a mutation in this C-terminal part of PHD1 does not 238 
disrupt the histone binding site, but still displays an incomplete inhibition of AIRE-dependent 239 
gene transcription (Figure 2B, Figure S3 and Table S3). AIRE sequencing revealed that the 240 
patient also had p.V484A; a sequence variant that has been described in a patient with 241 
alopecia and nail dystrophy (Buzi et al., 2003). We were unfortunately unable to perform an 242 
allele discrimination assay in this patient. 243 
Importantly, sequencing of 450 control blood donors did not reveal presence of any 244 
of the dominant negative PHD1 mutations, demonstrating that dominant PHD1 mutations 245 
are clearly over-represented among patients suffering from various forms of organ-specific 246 
autoimmunity.  247 
 248 
The frequency of dominant negative PHD1 AIRE mutations in populations 249 
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To better estimate the frequency of some of the dominant negative PHD1 AIRE mutations, 250 
we analyzed multiple exome chip datasets that were available, containing some of the PHD1 251 
AIRE sequence variations. Specifically, sequence analysis from existing exome chip datasets 252 
from a total of 1670 Scandinavian individuals (healthy controls (n=637), and patients with 253 
attention deficit (n= 589) or movement disorders (n=444)), we determined the minor allele 254 
frequency of p.V301M to be 0.00089 (i.e 3 out of 1667 persons), while other covered 255 
mutations p.G303S, p.R303Q, and p.R257* were not found. The relatively high frequency of 256 
the p.V301M dominant mutant was further validated by additional datasets obtained from 257 
public databases, including the recently published data from The Broad Institute (covering 258 
over 60 thousand individuals) (Exome Aggregation Consortium (ExAC), Cambridge, MA 259 
(URL: http://exac.broadinstitute.org)), 1000 Genome database 260 
(http://www.1000genomes.org) and the Washington Database (~6 thousand individuals) 261 
(Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: 262 
http://evs.gs.washington.edu/EVS/).  All above databases confirmed and broadened these 263 
findings and demonstrated that dominant-negative PHD1-mutations are present with minor 264 
allele frequency reaching 0.0009 (mainly p.V301M and p.R303Q) (Table 2). It should be 265 
stressed however, that most of the dominant negative PHD1 variants were not covered on 266 
these exom chips, suggesting that the actual frequency may be even higher. 267 
 268 
DISCUSSION 269 
Molecular aspects of dominant-negative mutations of AIRE 270 
Many proteins are active only in the form of a multimeric complex, composed of two 271 
or more copies of the same protein. It is well established that in many of these cases, mono-272 
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allelic mutations can completely or partially disrupt the structure and thereby the activity of 273 
the entire multimeric complex in a dominant-negative manner. Since AIRE was shown to 274 
form a homo-tetramer in vivo (Kumar et al., 2001), it is rather surprising that only one mono-275 
allelic mutation in the AIRE locus has been linked to APS-1 and/or other forms of organ-276 
specific autoimmune disorders so far. We identify several novel heterozygous missense 277 
mutations in AIRE, primarily clustered within its PHD1 zinc finger (Figure 4B), which are 278 
characterized by dominant inheritance, later debut, milder phenotypes, and reduced 279 
penetrance. Interestingly, most autosomal recessive missense mutations causing APS-1 are 280 
predominantly found within the CARD domain (Bjorses et al., 2000), suggesting that the 281 
recessive or dominant character of the given mutation is, to a large extent, determined by its 282 
position within the AIRE protein. This likely reflects the different and unique roles of the 283 
individual domains of the AIRE protein.  Specifically, while the CARD domain has been shown 284 
to be critical for AIRE homo-oligomerization and speckled nuclear localization (Bjorses et al., 285 
1999; Kumar et al., 2001), the PHD domain of AIRE functions as an epigenetic reader, 286 
specifically recognizing unmethylated lysine 4 on histone 3 (H3K4me0) (Org et al., 2008). The 287 
PHD1 domain was shown to be absolutely critical for /Z ?ƐƚƌĂŶƐĐƌŝƉƚŝŽŶ-transctivation 288 
activity, as well as for its capacity to prevent multiorgan autoimmunity in transgenic mouse 289 
models (Bjorses et al., 2000; Koh et al., 2010; Koh et al., 2008). In silico simulations revealed 290 
that the PHD1 residues N295-C310 are important in the intermolecular interactions with 291 
histone H3 residues (Figure 2B, Figure 3B and Table S3). PHD1 is unable to interact with 292 
H3K4me0 if the zinc chelating cysteines are mutated, as is the case for C311Y (Bottomley et 293 
al., 2005). The formation of salt-bridges between the side chains of H3 residue R2 and D312 294 
was shown to be crucial for binding specificity (Koh et al., 2008), explaining why the 295 
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structure is highly conserved in AIRE among different species and also in PHD-zinc finger 296 
domain-containing proteins (Figure S5).  297 
Unlike the PHD1 mutants, mutations clustered within the CARD domain of AIRE do 298 
not exert any dominant negative effect (Figure 2B, Figure S3 and Table S3). In homozygotes 299 
these mutations impact on AIRE oligomerization and correct nuclear localization (Bjorses et 300 
al., 1999; Kumar et al., 2001; Pitkanen et al., 2001), yet may be able to form oligomers when 301 
expressed along with WT AIRE (Figure 3A, Figure S4 and Table S2). Interestingly, truncating 302 
AIRE mutations such as p.R257* and p.C311* also behave in a recessive manner, in spite of 303 
their ability to co-localize and interact with WT-AIRE (Figure 3A, Figure S4 and Table S2). This 304 
suggests that the above truncations do not disrupt the core structure of the AIRE complex, 305 
necessary for its biological activity. Such core structure likely involves formation of functional 306 
dimers within the truncated tetramer (Figure 5A).  307 
It is therefore not entirely surprising that mono-allelic and dominant negative 308 
mutations in this domain will impact on the structure and thus the activity of the entire AIRE 309 
tetramer. However, such dominant effect seems to follow incomplete inheritance, as most 310 
of the patients develop milder phenotypes with later onset compared to patients with 311 
classical, autosomal recessive APS1. This could be because the AIRE tetramers still have 312 
some residual activity, and/or that some pure WT-AIRE tetramers are still formed and are 313 
sufficient to induce some level of self-tolerance.  Moreover, the extent of the dominant 314 
effect seems to depend on which residue is mutated. Our results suggest that mutations in 315 
residues 302 and 311 resemble more classical APS-1 than other mutations, although we 316 
observed large diversity within the two families with p.C311Y studied here. 317 
 318 
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Clinical aspects of dominant-negative mutations of AIRE 319 
The genetic contribution of AIRE to other autoimmune diseases than APS-1 has been 320 
studied by us and others, but in most cases only SNPs or a few common mutations have 321 
been analyzed, thereby overlooking rare mutations or large deletions (Jin et al., 2007; Pforr 322 
et al., 2006; Thomson et al., 2007; Torok et al., 2004; Turunen et al., 2006; Vaidya et al., 323 
2000). Although some heterozygous mutations in AIRE have been associated with 324 
autoimmunity in single patients (Table S4), a dominant negative effect on AIRE function was 325 
not considered in these cases. Here, we demonstrate for the first time that the heterozygous 326 
variants observed in the families as well as other mutations analyzed within AIRE exon 8 327 
have an inhibitory effect on AIRE-mediated transcription. This contrasts to classical APS-1 328 
with recessive inheritance and early presentation (mean age 9.1 years (Wolff et al., 2007a)); 329 
90% develops all three components by age 20 years (Wolff et al., 2007a), Organ-specific 330 
autoimmunity in the heterozygous  cases presents later (mean age 24.4 years, n = 12), 331 
progresses more slowly, fewer patients develop the diagnostic dyad, and the penetrance is 332 
incomplete (Figures 4B and 5B). This is reminiscent of autoimmune lymphoproliferative 333 
syndrome, which shows 60 % penetrance among family members harboring the same 334 
heterozygous gene mutation (Price et al., 2014), or to the incomplete penetrance seen in 335 
families carrying heterozygous CTLA4 mutations (Kuehn et al., 2014). More importantly, the 336 
unusual heterozygous cases may not even be recognized as APS-1 as many patients 337 
masquerade as common types of organ-specific autoimmunity in one or several organs. 338 
Thus, the original classification of APS-1 as a strictly autosomal recessive disease (with one 339 
exception (Cetani et al., 2001)) is obsolete. Instead, we propose that APS-1 exists in two 340 
ĨŽƌŵƐ P ?ŝ ? ‘ĐůĂƐƐŝĐĂů ? ?ĐŚĂƌĂĐƚĞƌŝǌĞĚďǇƌĞĐĞƐƐŝǀĞŝŶŚĞƌŝƚĂ Đ  ?ƉƌĞƐĞŶĐĞŽĨĂƚůĞĂƐƚƚǁŽŽĨƚŚƌĞĞ341 
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ŵĂŝŶĐŽŵƉŽŶĞŶƚƐ ?ĂŶĚŝŶƚĞƌĨĞƌŽŶĂŶƚŝďŽĚŝĞƐ ?ĂŶĚ ?ŝŝ ? ‘ŶŽŶ-ĐůĂƐƐŝĐĂů ? ?ĐŚĂƌĂĐƚĞƌŝǌĞĚďǇ342 
dominant heƚĞƌŽǌǇŐŽƵƐŵƵƚĂƚŝŽŶƐŵĂŝŶůǇŝŶ/Z ?ƐW, ?ǌŝŶĐĨŝŶŐĞƌĂŶĚĂŵŝůĚĞƌůĞƐƐ343 
penetrant autoimmune phenotype (Figure 5B). Families with dominant clustering of organ-344 
specific autoimmunity, especially when pernicious anemia and / or vitiligo manifests at early 345 
age, might have such mutations, although the clinical phenotype might be expanded when 346 
larger materials are investigated. Furthermore, it is reasonable to assume that mutation 347 
carriers have a significant risk for polyendocrinopathy, which should be reflected in their 348 
follow-up programs. Moreover, autoantibodies against interferons, hallmarks of classical 349 
APS-1, are much less prevalent in the non-classical form probably reflecting some residual 350 
AIRE-function at least for some of the PHD1 mutations. 351 
 Since deep DNA sequencing of thousands of different patients was beyond the scope 352 
of the current study, we cannot provide accurate estimates of the prevalence of non-353 
classical APS-1 since a population cohort with autoimmune phenotypes was not available. 354 
Based on our own data and publicly available databases representing patients with diverse 355 
conditions in different ethnic groups, a conservative estimate puts dominant AIRE mutations 356 
at a genotype frequency of 1-2 persons per thousand, not restricted to the Scandinavian 357 
population as also is underpinned by literature reports (Cervato et al., 2010; Ferrera et al., 358 
2007; Stolarski et al., 2006; Vogel et al., 2001) (Table 2 and Table S4). However, further 359 
studies are needed to establish the prevalence and risk associated with mutations in the 360 
PHD1 domain in larger populations. 361 
In conclusion, this study represents the first demonstration that AIRE mutations 362 
associate with common organ-specific autoimmunity with a variable phenotype ranging 363 
from classical APS-1 to a non-classical form that mimics common organ-specific 364 
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autoimmunity. Finally, our study provides important insights into the molecular mode of 365 
action of the AIRE protein and highlights unique structural properties that are required for 366 
/Z ?ƐďŝŽůŽŐŝĐĂůĂĐƚŝǀŝƚǇ ? 367 
 368 
EXPERIMENTAL PROCEDURES 369 
Patients 370 
Norwegian, Finnish, and Russian patients were recruited from the respective national patient 371 
registries and biobanks of patients with APS-1, adrenal insufficiency and polyendocrine syndromes. 372 
Vitiligo patients were recruited by the Sheffield Teaching Hospitals NHS Trust, Sheffield, UK; 373 
pernicious anaemia patients were recruited by Manchester Centre for Genomic Medicine, Central 374 
Manchester University Hospitals NHS Trust in collaboration with the Pernicious Anaemia Society of 375 
United Kingdom. For estimation of population frequencies of AIRE mutations, exome chip data from 376 
cohorts with healthy controls (n=637), and patients groups without known susceptibility for 377 
autoimmunity were available (for details, see Supplemental Methods). All participating patients 378 
signed an informed consent. Samples from blood donors were recruited from the Haukeland 379 
University Hospital blood bank. The study was approved by the Regional Ethics committees in each 380 
institution.  381 
 382 
AIRE sequencing, copy number analysis and microsatellite typing 383 
All 14 exons of the AIRE gene (EMBL acc. Number AJ009610) were amplified by PCR and sequenced 384 
as described previously (Wolff et al., 2007b). The PHD1 zinc finger is encoded by exon 8 (see 385 
Supplemental Methods). Copy number analysis was performed by duplex TaqMan real-time PCR 386 
assay (Boe Wolff et al., 2008). Microsatellite typing of the AIRE region was performed according to 387 
Myhre et al (Myhre et al., 2004). The samples used to estimate population frequencies for AIRE 388 
mutations were genotyped on the HumanExome 12v1_B (ADHD study) and HumanCoreExome 12v1-389 
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1 (movement disorders study) Bead chips respectively (Illumina Inc, San Diego, CA). For further 390 
information and analysis of data see Supplemental Methods in the Supplement. 391 
 392 
Assay of autoantibodies 393 
Autoantibodies typical of APS-1, were assayed by radioligand binding assays as previously described 394 
(Husebye et al., 1997; Oftedal et al., 2008) (Supplemental Methods). 395 
 396 
Assay of AIRE-regulated genes 397 
The human 4D6 thymic epithelial cell line was transfected with AIRE-containing plasmid constructs 398 
using the Fugene HD transfection reagent (Promega Corporation, Madison, WI, USA) according to the 399 
ŵĂŶƵĨĂĐƚƵƌĞƌƐ ?ƉƌŽƚŽĐŽů ?Mutations in AIRE were engineered using site-directed mutagenesis 400 
(Supplemental Methods). Genes previously shown to be regulated by AIRE (Abramson et al., 2010) 401 
were analyzed by quantitative PCR, and the comparative Ct-method (Applied Biosystems, Carlsbad, 402 
CA, USA) (SupplementalMethods). 403 
 404 
Immunofluorescence 405 
4D6 cells were grown on sterile coverslips and transfected with EGFP-AIRE and/or RFP-AIRE fusion 406 
plasmids using Fugene HD transfection reagent, and analyzed under a Zeiss LSM 510 META Laser 407 
Scanning confocal microscope (Supplemental Methods). 408 
 409 
Structure modelling 410 
Sequence alignment was made using Clustal Omega Multiple sequence alignment tool 411 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo). Modelling of PHD1 was 412 
performed using PyMOL and the coordinates of the PDB entry 1XWH (Bottomley et al., 2005).  413 
 414 
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Supplemental information includes supplemental methods, Supplemental figures S1-S5, 416 
Supplemental table S1-S5. 417 
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Figure 1. APS-1 family with dominant inheritance. (A) Pedigree showing the North-584 
African/Norwegian family with the dominantly inherited p.C311Y mutation. The lover panel 585 
show the heterozygous mutation in exon 8 revealed by Sanger sequencing. 586 
(C)Transcriptional regulation by WT AIRE and the different mutations. The AIRE-regulated 587 
gene keratin 14 (KRT14) was tested together with the AIRE-independent gene cyclin H 588 
(CCNH) and normalized against the endogenous control beta2-microglobulin (B2M). Cells 589 
were transfected with various amounts of WT AIRE and mutants, alone or in combinations. 590 
The results are shown as fold difference (FD) compared to cells transfected only with WT 591 
AIRE (dotted line), error bars are representing SEM.   592 
 593 
Figure 2. Heterozygous mutations in AIRE and the effect on gene regulation. (A) Model of 594 
the AIRE protein with domains and common mutations classified as recessive (black) and 595 
dominant (red). (B). The AIRE-regulated gene KRT14 (red bars), and CCNH not regulated by 596 
AIRE (blue bars). Transcriptional regulation by WT-AIRE and mutants was performed as 597 
described in Figure 1B. The results are shown as fold difference (FD) compared to cells 598 
transfected only with WT AIRE (dotted line), error bars are representing SEM. 599 
 600 
Figure 3. Subcellular co-localization of the mono-allelic variants.  (A) Confocal fluorescence 601 
images displaying the subcellular localization of WT-RFP-AIRE (red) and mutant-EGFP-AIRE 602 
(green) constructs. Overlay images shows the degree of co-localization (yellow). Nuclei were 603 
visualized with DAPI counterstain (blue). (B) The solution structure of the PHD1 domain of 604 
AIRE, showing the Zn
2+
  Wligating residues. Zn2+ shown as sphere, and cysteines as sticks. The 605 
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C311 mutation hotspot is shown in cyan (right). Modelling shows that the C311Y mutation 606 
would disrupt Zn
2+
 ligation. 607 
 608 
Figure 4. The AIRE PHD1-domain. (A) Pedigrees of families with p.C311Y (Family B), 609 
p.V301M (Family C) p.P326L (Family F) and p.G305S (Family G) AIRE mutations. (B) The AIRE 610 
protein with its different domains. The mutations investigated in this study are shown, now 611 
color-coded for dominant (red) and recessive (black). The AIRE PHD1 is shown, together with 612 
cake diagrams each representing one patient depicting clinical manifestations and 613 
autoantibodies. 614 
 615 
Figure 5. Dominant mutations in AIRE and organ-specific autoimmunity. (A) Schematic 616 
illustration of recessive and dominant AIRE mutations. The homozygous R257* truncated 617 
protein can form oligomers, but they lack critical domains. In the heterozygous state R257* 618 
does not interfere with WT-AIRE. PHD1 mutants can form oligomers but AIRE lack 619 
transcriptional activity due to its putative interaction with WT-AIRE. Formation of a small 620 
fraction of WT:WT oligomers may account for some induction of tolerance and a milder 621 
autoimmune phenotype. (B) Manifestations and autoantibodies in patients with recessive 622 
(from references (Meager et al., 2006; Perheentupa, 2006; Wolff et al., 2007a)) and 623 
dominant (this study) mutations. AI, adrenocortical insufficiency; CMC, chronic 624 
mucocutaneous candidiasis; HP, hypoparathyroidism; PA, pernicious anemia; V, vitiligo; n.a., 625 
data not available.626 
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Table 1. Families with heterozygous mutations in the AIRE gene, their manifestations and autoantibodies 
 
a
Family Patient YoB Mutation 
b
Manifestations 
c
Organ-specific 
autoantibodies 
d
Cytokine 
autoantibodies 
e
HLA class II genotypes stratified 
to AI risk 
A I:2 1951 p.C311Y;WT CMC, AI, PA, PDI, EH SCC IFN-ʘ ?/&E-ɲ2  Neutral 
 II:1 1971 p.C311Y;WT HP, PA, EH, POI NALP-5 IFN-ʘ ?/&E-ɲ2 Protective 
 II:2 1988 p.C311Y;WT AA, nail dystrophy  IFN-ʘ ?IFN-ɲ2 Neutral 
 II:3 1990 p.C311Y;WT  TH  Protective 
 II:4 1995 p.C311Y;WT HP, POI NALP-5 IFN-ʘ ?/&E-ɲ2 Neutral 
 II:5 1998 WT;WT    Protective 
B I:2 1928 p.C311Y;WT PA, Blind, T2D 21-OH, NALP-5, AADC, IF  Neutral 
 II:1 1959 p.R257*;WT L, oral cancer   Protective 
 II:3 1961 p.C311Y;p.R257* CMC, AI, POI, A 21-OH, SCC, 17-0H, AADC, 
TH 
IFN-ʘ ?/&E-ɲ ? ?/>-17F, 
IL-22 
Protective 
 II:4 1965 p.C311Y;p.R257* HP, CMC, AI, POI, A 21-OH, SCC, 17-OH, TPH-1, 
NALP-5 
IFN-ʘ ?/&E-ɲ ? ?/>-17F, 
IL-22 
Protective 
 III:1 1984 p.C311Y;WT PA, V GPCA, IF  Neutral 
C I:2 1955 p.V301M;WT AI, AT, POI 21-OH, AADC
f
 IL-17F Very High 
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 II:1 1977 WT;WT  n.a n.a n.a. 
 II:2 1980 p.V301M;WT   IL-17F Neutral 
D  2010 p.C302Y;WT HP 21-OH, NALP-5 IFN- ʘ n.a 
E  2001 p.C302Y;WT HP NALP-5 IFN-ʘ n.a. 
F I:1 1935 p.P326L;WT    Neutral 
 I:2 1943 p.P326L;WT    Neutral 
 I:3 1943 WT;WT    Intermediate 
 I:4 1944 p.P326L;WT Low B12 GPCA  High 
 II:1 1967 p.P326L;WT    Intermediate 
 II:3 1972 p.P326L;WT AI, PA, V, 
hypothyroidism 
21-OH  High 
 II:4 1974 p.P326L;WT  TPH-1  High 
 II:5 1984 WT;WT  GAD, TPH-1  Intermediate 
 III:1 1992 p.P326L;WT V GPCA  Intermediate 
 III:2 2005 p.P326L;WT V n.a. n.a. Intermediate 
G I:1  n.a PA n.a n.a n.a 
 I:2  n.a No autoimmunity n.a n.a n.a 
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 II:1 1934 n.a No autoimmunity n.a n.a n.a 
 II:2  n.a PA, hypothyroidism, 
cirrhosis 
n.a n.a n.a 
 II:3  n.a PA n.a n.a n.a 
 III:1 1959 WT;WT No autoimmunity n.a n.a n.a 
 III:2  p.G305S;WT PA IF  n.a 
 III:3 1972 p.G305S;WT No autoimmunity n.a n.a n.a 
H   p.R316W, 
p.C322del13;WT 
PA   Intermediate 
I
g
  1975 p.R328Q;WT V, low normal B12 GPCA, GAD n.a. High 
a
All members of families were analyzed for autoantibodies against 21-OH, 17-OH, GAD, SCC, AADC, TPH-1, TH, NALP-5, IFN-ʘ ?/&E-ɲ2, IL-17F and IL-22, unless otherwise 
stated. 
b
A, asplenia; AA, alopecia areata; AI, adrenocortical insufficiency; AT, autoimmune thyroid disease; CMC, chronic mucocutaneous candidiasis; EH, enamel hypoplasia; HP, 
hypoparathyroidism; L, lupus erythematosus disseminates; PA, pernicious anemia; PDI, partial diabetes insipidus; POI, primary ovarian insufficiency; T2D, type 2 diabetes; V, 
vitiligo. Main components of APS-1 are indicated in bold 
c
AADC, aromatic L-amino acid decarboxylase; GAD, glutamic acid decarboxylase; GPCA, gastric parietal cell antibody; ICA, islet cell antibody; IF, intrinsic factor; 17-OH, 17-
hydroxylase; 21-OH, 21-hydroxylase; NALP-5, NACHT leucine-rich repeat protein 5; SCC, side-chain cleavage enzyme; TH, tyrosine hydroxylase; TMH, thyroid microsomal 
hemoagglutinating; TPH-1, tryptophan hydroxylase; n.a., data not available. 
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d
IFN-ɲ ? ?ŝŶƚĞƌĨĞƌŽŶ-alpha 2; IFN-ʘ ?ŝŶƚĞƌĨĞƌŽŶ-omega; IL-17F; interleukin-17F; IL-22, interleukin-22;  n.a., data not available. 
e
Risk assessment for HLA genotypes were defined as in Erichsen et al.,  JCEM 2009. Full HLA class II haplotypes are given in Supplemental table S5. The genotypes conferring 
 “ǀĞƌǇŚŝŐŚ ?ĂŶĚ “ŚŝŐŚ ?ƌŝƐŬŽĨĚĞǀĞůŽƉŝŶŐ/ĂůƐŽĐŽŶĨĞƌŝŶĐƌĞĂƐĞĚƌŝƐŬŽĨĚĞǀĞůŽƉŝŶŐW ?>ĂŚŶĞƌĞƚĂů., Dig Liver Dis 2010).       
f
Initially positive for autoantibodies against AADC, but negative in recent samples. 
g
Immunofluorescence testing for adrenal, ovarian and pituitary autoantibodies was negative, as were anti-mitochondrial, anti-smooth muscle and thyroid peroxidase (TPO) 
autoantibodies. The patient previously tested positive for autoantibodies against tyrosinase and tyrosinase-related protein 1 and 2.  
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Table 2.  Minor allele frequency (MAF) of missense mutations within AIRE exon 8 (PHD 1 protein domain) 
 
  Norwegian exome data  ExAC Browser 1000 Genomes Genome Variant Server 
Variant 
Protein 
effect 
Allele 
count 
Allele 
No 
MAF 
Allele 
Count 
Allele No MAF 
Allele 
Count 
Allele 
No 
MAF 
Allele 
Count 
Allele 
No 
MAF 
21:45710990 
G / A 
p.E298K  n.a n.a  n.a  1 121632 0.000008222     n.a n.a n.a n.a 
21:45710995 
T / G 
p.C299W  n.a n.a   n.a 1 121584 0.000008225     n.a n.a n.a n.a 
21:45710999 
G / A 
rs150634562 
p.V301M  3 3340  0.00089  111 121496 0.0009136* 2 5006 0.00039 5 13001 0.00038 
21:45711005 
C / T 
p.R303W  n.a n.a   n.a 1 121256 0.000008247     n.d 2 13002 0.00015 
21:45711006 
G / A 
rs139808903 
p.R303Q  n.d  n.d  n.d 22 121228 0.0001815**     n.a n.a n.a n.a 
21:45711014 
G / A 
p.G306R  n.a n.a   n.a 1 121096 0.000008258     n.a n.a n.a n.a 
21:45711025 
C / G 
rs74162062 
p.I309M  n.a n.a   n.a 14 120718 0.0001160^     n.d n.a n.a n.a 
21:45711044 
C / T 
p.R316W  n.a n.a   n.a 4 119274 0.00003354 2 8596 0.00023 2 13002 0.00015 
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rs139874934 
21:45711044 
C / G 
rs139874934 
p.R316G  n.a n.a   n.a 1 119274 0.000008384     n.a n.a n.a n.a 
21:45711045 
G / A 
p.R316Q  n.a n.a   n.a 4 119214 0.00003355 1 760 0.0013 n.a n.a n.a 
21:45711054 
A / C 
p.H319P  n.a n.a   n.a 3 117232 0.00002559     n.a n.a n.a n.a 
21:45711075 
C/A 
rs179363885 
p.P326Q  n.a n.a   n.a n.a n.a n.a     n.d n.a n.a n.a 
21:45711075 
C/T 
rs179363888 
p.P326L  n.a n.a   n.a n.a n.a n.a     n.d n.a n.a n.a 
21:45711080 
C / T 
rs74162063 
p.R328W  n.d  n.d  n.d 21 116188 0.0001807^^     n.d 10 12982 0.00077 
21:45711081 
G / A 
p.R328Q  n.a n.a   n.a 4 116112 0.00003445     n.d n.a n.a n.a 
21:45711092 
A / C 
p.S332R  n.a n.a   n.a 1 114898 0.000008703     n.a n.a n.a n.a 
 
n.a= not analysed in this dataset 
n.d = no frequency determined  
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*The majority mutations are found in European (minus Finnish), followed by Finnish, South Asian and African populations 
**The majority mutations are found in European (minus Finnish), followed by Latino populations 
^The majority mutations are found in European (minus Finnish), followed by South Asian population 
^^The majority mutations are found in European (minus Finnish), followed by Finnish population 
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